SlimSEB

Chino, Calif. – September 13, 2026 -- Specialty Enzymes & Probiotics has published dual-track research showing its ingredient SlimSEBTM reduces post-meal blood sugar spikes by 16.90% in a controlled human clinical trial, providing formulators with clinically backed data for glucose-support supplements.

Clinical trial confirms 16.90% reduction in glucose AUC

In a double-blind, randomized, placebo-controlled crossover trial, subjects supplemented with SlimSEBTM showed a 16.90% reduction in Area Under the Curve (AUC), a standard measure of post-prandial glycemic response. The result demonstrates statistically significant improvement in blood sugar control following meals.